Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.07 is 18% below its 5-year average of -0.91, near the low end of its 5-year range (-1.27–-0.42).
4.89% above its 12-month average of -1.13.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.28.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.07
EARNINGS PER SHARE (EPS) AVG TTM
-1.13
EARNINGS PER SHARE (EPS) AVG 3Y
-1.07
EARNINGS PER SHARE (EPS) AVG 5Y
-0.91
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.89%
CURRENT VS 3Y AVG
-0.21%
CURRENT VS 5Y AVG
-18.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Coya Therapeutics, Inc.
Market Cap
$117.47M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$116.75M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$116.47M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
Market Cap
$116.04M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$116.14M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$115.59M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$121.11M
Earnings Per Share (EPS)
-1.22
TTM Avg
-1.33
3Y Avg
-1.36
5Y Avg
-1.18
Market Cap
$121.25M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
Market Cap
$113.34M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $117.47M | -1.07 | -1.13 | -1.07 | -0.91 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.75M | -4.09 | -2.59 | -6.03 | -6.97 |
| BGM Group Ltd. (BGM)vs › | $116.47M | N/A | -5.70 | -9.83 | -0.70 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.04M | -1.08 | -1.62 | -1.56 | -1.43 |
| Genelux Corporation (GNLX)vs › | $116.14M | -0.89 | -0.91 | -0.79 | -0.74 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.59M | -0.47 | -0.87 | -1.14 | -0.92 |
| Seer, Inc. (SEER)vs › | $121.11M | -1.22 | -1.33 | -1.36 | -1.18 |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | -0.28 | -1.88 | -2.46 | -1.80 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $113.34M | -1.52 | -3.16 | -3.35 | -6.72 |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.95M | -0.54 | -0.92 | -84.40 | -674.41 |
Trailing EPS (TTM)
$-1.07
Forward EPS (Est.)
$-1.33
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.27 |
| 2024-12-31 | -0.98 |
| 2023-12-31 | -0.79 |
| 2022-12-31 | -1.23 |
| 2021-12-31 | -0.74 |
| 2020-12-31 | -0.42 |
